Doc's note: One of the best buy-in opportunities you can find as an investor is a company that is doing well, but other investors are ignoring.

As my friend Joel Litman – from our corporate affiliate Altimetry – explains today, there's one company that, while it's seeing a big boost thanks to AI, the markets aren't convinced of a turnaround. According to Joel, the stock is likely to produce a big win, especially for those who get in while it's trading at a discount...

Qualcomm (QCOM) spent years trying to convince investors that it could do more than power smartphones...

The company dominated the chip market for those devices. Then it expanded into cars, connected devices, and PCs.

This was right around the time investor attention shifted to AI. But Qualcomm couldn't keep up.

Its revenue peaked at $44 billion in fiscal year 2022 and then slipped to $36 billion during the handset downturn. (Global smartphone shipments and sales fell about 4% in 2023.)

The business survived the slump, recovering to $44.3 billion in fiscal year 2025. But it has been treading water since then.

Today, we'll look at how Qualcomm is finally entering the AI market, and why investors have yet to price in a return to stronger profitability.

Qualcomm's data-center push is no longer a side project...

Smartphones run on a tight power supply, so their batteries need to last. Data centers now face a similar constraint... at a much larger scale.

At its June 24 Investor Day, Qualcomm unveiled its infrastructure roadmap for the AI and data-center markets. This included the Dragonfly C1000 data-center central processing unit ("CPU") and other new products.

Its data-center lineup aims to maximize performance per watt and lower total costs over the life of chips.

According to Qualcomm, Meta Platforms (META) agreed to use the Dragonfly C1000, and future iterations of the CPU, in its AI infrastructure starting in 2028.

AI power demand keeps growing. Yet power availability is becoming one of the biggest bottlenecks for hyperscale operators.

Qualcomm is trying to bring its "wireless DNA" into that environment.

Its data-center expansion should produce billions of dollars in revenue starting next year...

Qualcomm lifted its fiscal 2029 non-handset revenue target to $40 billion, roughly twice its prior goal. At least $15 billion is expected to come from data centers.

That's a major shift for a company that investors still associate with cellphones.

And that seems to be what the market is worried about... Wall Street analysts expect Qualcomm's smartphone revenue to fall between $5 billion and $6 billion heading into next year.

This is exactly why the data-center pivot matters.

Despite record demand, investors aren't optimistic about Qualcomm's long-term performance...

We can see this through our Embedded Expectations Analysis ("EEA") framework.

The EEA starts by looking at a company's current stock price. From there, we can calculate what the market expects from the company's future cash flows. We then compare that with our own cash-flow projections.

In short, it tells us how well a company has to perform in the future to be worth what the market is paying for it today.

Over the past decade, Qualcomm's Uniform return on assets ("ROA") was consistently above 20%. That means the company generated big profits through its core chip franchises.

When the handset downturn hit, the company's revenue fell and investor confidence collapsed. After three rough years, the market appears to be treating the 20% Uniform ROA as a hard cap, even though Qualcomm has spent years performing above that level.

Take a look...

The market expects the post-2022 version of Qualcomm to persist, even as the company's revenue mix shifts toward a much bigger AI opportunity.

Qualcomm missed the first wave of the AI trade, but it can still win...

Qualcomm's AI business is young... Its data-center products are only beginning to ramp up.

That said, the company now has a major hyperscale customer in Meta... And it's inking agreements for a brand-new chip line.

Management has nearly doubled its revenue expectations for non-smartphone chips by 2029. That tells us the company's growth will be stronger than investors currently expect.

They've spent years learning to discount Qualcomm.

But now, it's reverting to the profitability investors used to see... while staking its claim in an entirely new market.

Regards,

Joel Litman

Editor's note: Last week, Joel revealed five little-known stocks he believes could become the biggest winners of America's AI race. He believes July 10 could mark a major turning point in this race because on that day, three powerful market catalysts are set to converge at once thanks to the orders of President Donald Trump.

If you missed Joel's "AI Super Summit," click here to watch before it goes offline.

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top